RegenETP Management
Management criteria checks 4/4
RegenETP's CEO is Richard Hague, appointed in Apr 2020, has a tenure of 4.08 years. total yearly compensation is $479.81K, comprised of 93.5% salary and 6.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth $1.33K. The average tenure of the management team and the board of directors is 5 years and 6.9 years respectively.
Key information
Richard Hague
Chief executive officer
US$479.8k
Total compensation
CEO salary percentage | 93.5% |
CEO tenure | 4.1yrs |
CEO ownership | 0.6% |
Management average tenure | 5yrs |
Board average tenure | 6.9yrs |
Recent management updates
Recent updates
PolarityTE down 10% on lower-than-expected Q2 revenue
Aug 12Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?
Mar 08Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation
Nov 16PolarityTE Is Not A DeFi Coin
Jul 19Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?
Jun 04PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint
May 10What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition
Feb 19PolarityTE to raise up to $10M with at-the-market offering
Jan 12PolarityTE under pressure on pricing $8M registered direct offering
Dec 22PolarityTE perks up after securing first U.S. patent
Nov 30PolarityTE EPS beats by $0.02, beats on revenue
Nov 09CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2023 | n/a | n/a | -US$8m |
Dec 31 2022 | US$480k | US$449k | -US$8m |
Sep 30 2022 | n/a | n/a | -US$16m |
Jun 30 2022 | n/a | n/a | -US$13m |
Mar 31 2022 | n/a | n/a | -US$17m |
Dec 31 2021 | US$1m | US$359k | -US$30m |
Sep 30 2021 | n/a | n/a | -US$32m |
Jun 30 2021 | n/a | n/a | -US$38m |
Mar 31 2021 | n/a | n/a | -US$47m |
Dec 31 2020 | US$996k | US$358k | -US$43m |
Sep 30 2020 | n/a | n/a | -US$54m |
Jun 30 2020 | n/a | n/a | -US$70m |
Mar 31 2020 | n/a | n/a | -US$80m |
Dec 31 2019 | US$2m | US$273k | -US$92m |
Compensation vs Market: Richard's total compensation ($USD479.81K) is about average for companies of similar size in the US market ($USD663.50K).
Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.
CEO
Richard Hague (63 yo)
4.1yrs
Tenure
US$479,808
Compensation
Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 4.1yrs | US$479.81k | 0.62% $ 1.3k | |
Chief Scientific Officer and VP of R&D | 5.8yrs | no data | no data | |
Vice President of Investor Relations & Strategy | 6yrs | no data | no data | |
Chief Legal Officer | no data | no data | no data | |
Vice President of Marketing & Public Relations | no data | no data | no data | |
Vice President of Sales | 5.8yrs | no data | no data | |
Senior VP of Corporate Development & President of Contract Services | no data | no data | no data | |
Chief Medical Officer | 2.7yrs | no data | no data | |
Senior Vice President of Manufacturing Operations | 1.5yrs | no data | no data |
5.0yrs
Average Tenure
Experienced Management: RGTP.Q's management team is considered experienced (5 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | less than a year | US$479.81k | 0.62% $ 1.3k | |
Member of Clinical Advisory board | no data | no data | no data | |
Member of Clinical Advisory Board | 7.4yrs | no data | no data | |
Member of Clinical Advisory Board | 7.4yrs | no data | no data | |
Member of Clinical Advisory Board | 7.4yrs | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | 6.9yrs | no data | no data | |
Member of Clinical Advisory Board | 6.9yrs | no data | no data | |
Member of Clinical Advisory Board | 6.9yrs | no data | no data |
6.9yrs
Average Tenure
Experienced Board: RGTP.Q's board of directors are considered experienced (6.9 years average tenure).